Nothing Special   »   [go: up one dir, main page]

HK1203499A1 - 吡咯 並三嗪類化合物，其製備方法及用途 - Google Patents

吡咯 並三嗪類化合物，其製備方法及用途

Info

Publication number
HK1203499A1
HK1203499A1 HK15104065.5A HK15104065A HK1203499A1 HK 1203499 A1 HK1203499 A1 HK 1203499A1 HK 15104065 A HK15104065 A HK 15104065A HK 1203499 A1 HK1203499 A1 HK 1203499A1
Authority
HK
Hong Kong
Prior art keywords
pyrrolo
preparation
application
triazine compound
triazine
Prior art date
Application number
HK15104065.5A
Other languages
English (en)
Inventor
楊春皓
蒙凌華
陳艷紅
王祥
譚村
李家鵬
丁健
陳奕
Original Assignee
Shanghai Inst Materia Medica
Shanghai Haihe Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Inst Materia Medica, Shanghai Haihe Pharmaceutical Co Ltd filed Critical Shanghai Inst Materia Medica
Publication of HK1203499A1 publication Critical patent/HK1203499A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
HK15104065.5A 2012-05-31 2015-04-27 吡咯 並三嗪類化合物，其製備方法及用途 HK1203499A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201210177980.3A CN103450204B (zh) 2012-05-31 2012-05-31 吡咯[2，1-f][1，2，4]并三嗪类化合物，其制备方法及用途
PCT/CN2013/074559 WO2013177983A1 (zh) 2012-05-31 2013-04-23 吡咯[2，1-f][1，2，4]并三嗪类化合物，其制备方法及用途

Publications (1)

Publication Number Publication Date
HK1203499A1 true HK1203499A1 (zh) 2015-10-30

Family

ID=49672377

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15104065.5A HK1203499A1 (zh) 2012-05-31 2015-04-27 吡咯 並三嗪類化合物，其製備方法及用途

Country Status (14)

Country Link
US (1) US9447101B2 (zh)
EP (1) EP2857403B1 (zh)
JP (1) JP6067107B2 (zh)
KR (1) KR101824299B1 (zh)
CN (1) CN103450204B (zh)
AU (1) AU2013270326B2 (zh)
BR (1) BR112014029708B1 (zh)
CA (1) CA2874062C (zh)
ES (1) ES2703934T3 (zh)
HK (1) HK1203499A1 (zh)
MX (1) MX359207B (zh)
RU (1) RU2589053C1 (zh)
SG (1) SG11201407752YA (zh)
WO (1) WO2013177983A1 (zh)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9724352B2 (en) * 2012-05-31 2017-08-08 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Pyrrolo[2,1-F[1,2,4]triazine compounds, preparation methods and applications thereof
US9447105B2 (en) 2013-01-24 2016-09-20 Council Of Scientific & Industrial Research Triazine compounds and a process for preparation thereof
WO2016064957A1 (en) 2014-10-22 2016-04-28 Bristol-Myers Squibb Company Bicyclic heteroaryl amine compounds as pi3k inhibitors
EP3209665B1 (en) 2014-10-22 2019-08-14 Bristol-Myers Squibb Company Substituted pyrrolotriazine amine compounds as pi3k inhibitors
WO2017004134A1 (en) * 2015-06-29 2017-01-05 Nimbus Iris, Inc. Irak inhibitors and uses thereof
WO2017040448A1 (en) * 2015-08-31 2017-03-09 Bristol-Myers Squibb Company Tgf beta receptor antagonists
EP3475285B1 (en) * 2016-06-25 2022-02-09 Suzhou Kintor Pharmaceuticals, Inc. Mechanistic target of rapamycin signaling pathway inhibitors and therapeutic applications thereof
CN109111447A (zh) * 2017-06-23 2019-01-01 中国科学院上海药物研究所 7-位取代吡咯并三嗪类化合物或其药学上可用的盐，及其制备方法和用途
CN111247150B (zh) * 2017-08-15 2022-11-08 石药集团中奇制药技术（石家庄）有限公司 Fgfr抑制剂及其医药用途
GB201720989D0 (en) * 2017-12-15 2018-01-31 Glaxosmithkline Ip Dev Ltd Chemical compounds
CA3154079A1 (en) * 2019-09-19 2021-03-25 Totus Medicines Inc. Therapeutic conjugates
EP4165045A4 (en) * 2020-06-05 2024-07-03 Univ Monash DOUBLE KINASE-BROMODOMAIN INHIBITORS
CN112851563A (zh) * 2020-12-30 2021-05-28 安徽金鼎医药股份有限公司 N-氨基-3-氮杂双环[3,3,0]辛烷盐酸盐的合成工艺
CN118119383A (zh) * 2021-09-10 2024-05-31 上海海和药物研究开发股份有限公司 包含PI3Kα抑制剂的药物组合
CN117126164B (zh) * 2023-08-30 2024-09-27 山东轩硕医药科技有限公司 一种吡咯并三嗪类化合物，其制备方法及用途

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6867300B2 (en) 2000-11-17 2005-03-15 Bristol-Myers Squibb Company Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
TWI329112B (en) 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
TW200420565A (en) 2002-12-13 2004-10-16 Bristol Myers Squibb Co C-6 modified indazolylpyrrolotriazines
MY145634A (en) 2003-12-29 2012-03-15 Bristol Myers Squibb Co Pyrrolotriazine compounds as kinase inhibitors
WO2006044687A2 (en) * 2004-10-15 2006-04-27 Takeda San Diego, Inc. Kinase inhibitors
US7151176B2 (en) 2004-10-21 2006-12-19 Bristol-Myers Squibb Company Pyrrolotriazine compounds
TW200635927A (en) 2004-12-22 2006-10-16 Bristol Myers Squibb Co Synthetic process
US7619083B2 (en) 2005-07-01 2009-11-17 Bristol-Myers Squibb Company Intermediates useful in preparing certain pyrrolotriazine compounds and process for making such intermediates
US7514435B2 (en) 2005-11-18 2009-04-07 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
CN101511835B (zh) 2006-07-07 2013-11-27 布里斯托尔-迈尔斯斯奎布公司 吡咯并三嗪激酶抑制剂
DK2050749T3 (en) * 2006-08-08 2018-01-08 Chugai Pharmaceutical Co Ltd PYRIMIDINE DERIVATIVES AS PI3K INHIBITOR AND USE THEREOF
ES2544082T3 (es) * 2006-12-07 2015-08-27 F. Hoffmann-La Roche Ag Compuestos inhibidores de fosfoinosítido 3-quinasa y métodos de uso
EP2114946A2 (en) 2007-01-02 2009-11-11 Brystol-Myers Squibb Company Intermediate useful in preparing certain pyrrolotriazine compounds and a process for making the intermediate
CN101687874B (zh) 2007-04-18 2013-01-30 百时美施贵宝公司 吡咯并三嗪激酶抑制剂
US8124759B2 (en) 2007-05-09 2012-02-28 Abbott Laboratories Inhibitors of protein kinases
CA2702838A1 (en) * 2007-10-16 2009-04-23 Wyeth Llc Thienopyrimidine and pyrazolopyrimidine compounds and their use as mtor kinase and pi3 kinase inhibitors
TW200938201A (en) * 2008-02-07 2009-09-16 Chugai Pharmaceutical Co Ltd Pyrrolopyrimidine derivative as PI3K inhibitor and use thereof
WO2010002954A1 (en) * 2008-07-02 2010-01-07 Wyeth (2-aryl-7h-pyrrolo[2,3-d]pyrimidin-4-yl)morpholine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
WO2010002472A1 (en) 2008-07-02 2010-01-07 Ambit Biosciences Corporation Jak kinase modulating compounds and methods of use thereof
WO2010092340A1 (en) * 2009-02-13 2010-08-19 Ucb Pharma S.A. Fused pyridine and pyrazine derivatives as kinase inhibitors
DK2419429T3 (da) * 2009-04-16 2014-06-23 Ct Nac De Investigaciones Oncológicas Cnio Imidazopyraziner som inhibitorer af proteinkinaser
ES2627703T3 (es) * 2010-01-22 2017-07-31 Fundación Centro Nacional De Investigaciones Oncológicas Carlos Iii Inhibidores de PI3·quinasa
WO2011141713A1 (en) * 2010-05-13 2011-11-17 Centro Nacional De Investigaciones Oncologicas (Cnio) New bicyclic compounds as pi3-k and mtor inhibitors
CN102675323B (zh) 2012-06-01 2014-04-09 南京药石药物研发有限公司 吡咯并[2,1-f][1,2,4]三嗪衍生物及其抗肿瘤用途

Also Published As

Publication number Publication date
WO2013177983A1 (zh) 2013-12-05
EP2857403B1 (en) 2018-10-10
MX2014014622A (es) 2015-08-10
AU2013270326A1 (en) 2014-12-18
ES2703934T3 (es) 2019-03-13
JP2015518010A (ja) 2015-06-25
MX359207B (es) 2018-09-19
CA2874062C (en) 2015-09-22
BR112014029708A2 (pt) 2017-06-27
SG11201407752YA (en) 2015-01-29
KR101824299B1 (ko) 2018-03-14
RU2589053C1 (ru) 2016-07-10
BR112014029708B1 (pt) 2023-05-02
CN103450204A (zh) 2013-12-18
BR112014029708A8 (pt) 2021-09-08
AU2013270326B2 (en) 2016-07-14
US20150141644A1 (en) 2015-05-21
JP6067107B2 (ja) 2017-01-25
US9447101B2 (en) 2016-09-20
EP2857403A1 (en) 2015-04-08
KR20150009565A (ko) 2015-01-26
CA2874062A1 (en) 2013-12-05
EP2857403A4 (en) 2015-10-21
CN103450204B (zh) 2016-08-17

Similar Documents

Publication Publication Date Title
HK1203499A1 (zh) 吡咯 並三嗪類化合物，其製備方法及用途
IL269797B (en) Antimicrobial solid surfaces and treatments and methods for their preparation
EP2727580A4 (en) COMPOSITION CONTAINING ASTAXANTHIN, METHOD FOR PRODUCING THE SAME, AND COSMETIC PRODUCT THEREOF
EP2830152A4 (en) ANTENNA ASSEMBLY AND METHOD FOR MANUFACTURING THE SAME
EP2796442A4 (en) ANALOG COMPOUND FROM A CAJANINE STRUCTURE, MANUFACTURING METHOD AND USE THEREOF
EP2816012A4 (en) MONOLITE OF A MACROPOROUS TITANIUM COMPOUND AND METHOD FOR THE PRODUCTION THEREOF
MY156744A (en) Antioxidant, antioxidant composition, and method producing the same
GB201208548D0 (en) Compound and method
PT2797436T (pt) Métodos para preparação de bebidas à base de plantas
EP2693564A4 (en) AMPLIFICATION ANTENNA AND METHOD FOR MANUFACTURING THE SAME
EP2763998A4 (en) TRI-HETEROCYCLIC DERIVATIVES, MANUFACTURING METHOD AND USES THEREOF
EP2897689A4 (en) COMPOSITIONS AND METHODS OF TREATING ALOPEZIA
EP3040308A4 (en) Pentasil-type zeolite, and method for manufacturing same
IL235949A0 (en) Pyrrolo [2,1-f] [1,2,4] triazine derivative and uses thereof for the treatment of tumors
EP2813495A4 (en) 2-ARYLBENZOFURAN-7-FORMAMIDE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND USE THEREOF
EP2671878A4 (en) SUBSTITUTED N-PENTANAMIDE COMPOUNDS, PREPARATION METHODS AND USES THEREOF
HRP20181326T1 (hr) Pesticidni pripravak i postupak za njegovu proizvodnju
EP2860181A4 (en) CONDENSED PYRIMIDINE COMPOUND, AND PREPARATION METHOD, INTERMEDIATE, COMPOSITION AND USES OF SAID COMPOUND
PL2723743T3 (pl) Pochodne 10H-benzo[g]pterydyno-2,4-dionu, sposób ich wytwarzania i ich zastosowanie
EP2669292A4 (en) RIBOFURANOSYL-PURINE COMPOUND, PROCESS FOR PREPARING THE SAME, AND USE THEREOF
IL235805A (en) Pyrimidinyl-Diazaspiro compound and process for preparation
EP2928693A4 (en) DECORLAMINATE AND METHOD FOR THE PRODUCTION THEREOF
EP2778168A4 (en) PYRROLO-PYRROLEDION-THENCHINONE COMPOUND AND METHOD OF MANUFACTURING THEREOF
EP2905274A4 (en) IMID compound, method for producing the same and use as an insecticide
EP2805946A4 (en) AMINO-ETHEROARYL COMPOUND, METHOD OF MANUFACTURING THEREOF AND USE THEREOF